Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;29(2):75-81.
doi: 10.1097/dbp.0b013e31815f24f7.

Stimulant medication treatment of target behaviors in children with autism: a population-based study

Katherine Nickels  1 , Slavica K Katusic, Robert C Colligan, Amy L Weaver, Robert G Voigt, William J Barbaresi
Affiliations

Stimulant medication treatment of target behaviors in children with autism: a population-based study

Katherine Nickels et al. J Dev Behav Pediatr. 2008 Apr.

Abstract

Objective: This study provides detailed information about stimulant medication treatment for the target symptoms of hyperactivity, impulsivity, disinhibition, and inattention in children with autism.

Methods: In a previous study, 124 subjects fulfilling DSM-IV-based research criteria for autistic disorder were identified among all 0-21 year old residents of Olmsted County, MN from 1976-1997. For each of these 124 children with research-identified autism, information was abstracted on all prescribed psychopharmacological medications.

Results: Psychostimulants were used to treat 52.4% (N = 65) of the 124 subjects. The median total duration of psychostimulant treatment was 4.0 years. There were 398 episodes of psychostimulant treatment. Favorable responses were associated with 69.4% of treatment episodes. Of the 398 episodes of stimulant treatment, 16.8% were associated with a documented side effect. At least one side effect was experienced by 66% of the children.

Conclusion: These results indicate that psychostimulants are commonly prescribed for children with autism, and suggest that these medications may improve the target symptoms of hyperactivity, impulsivity, disinhibition and inattention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram describing ascertainment of research-identified autism incident cases among residents of Olmsted County, Minnesota, age ≤ 21 years, during 1976-1997. IQ= Intelligence Quotient. DQ=developmental quotient. * At least two unique symptoms of impaired reciprocal social interaction, at least one symptom of impaired communication, at least one symptom of unusual/repetitive behavior, and a total of at least six unique symptoms of autism.
See this image and copyright information in PMC

References

    1. Volkmar FR, Pauls D. Autism. Lancet. 2003 Oct 4;362(9390):1133–1141. - PubMed
    1. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):312–315. - PubMed
    1. Association AP. Diagnostic and statistical manual of mental disorders text revision. 4th. Washington, D.C.: 2000.
    1. Association AP. Diagnostic and statistical manual of mental disorders. Washington, D.C.: 1994. pp. 65–78.
    1. Randomized, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005 Nov;62(11):1266–1274. - PubMed

Publication types

Substances